Clinical and prognostic significance of expression of phosphoglycerate mutase family member 5 and Parkin in advanced colorectal cancer

Table 3 Multivariate analysis of overall survival and progression-free survival for colorectal cancer by Cox regression

Variable	OS			PFS
	HR	95%CI	P value	HR	95%CI	P value
Tumor site (colon/rectum)	0.554	0.271-1.135	0.106	0.871	0.449-1.686	0.681
Size of the tumor, cm (> 4/≤ 4)	1.393	0.692-2.806	0.353	1.667	0.892-3.115	0.109
Degree of differentiation (poor/mucinous, well/moderate)	1.077	0.549-2.114	0.829	1.272	0.683-2.370	0.448
Tumor stage (III-IV/I-II)	1.978	0.264-14.799	0.506	1.122	0.166-7.577	0.906
Tumor invasion depth (T4/T2-T3)	1.551	0.752-3.199	0.234	1.439	0.744-2.786	0.280
Lymph node status (N1-N2/N0)	1.133	0.167-7.697	0.899	1.699	0.265-10.896	0.576
Distant metastasis (present/absent)	2.874	1.066-7.743	0.037	2.713	1.109-6.640	0.029
PGAM5 (low/high)	0.251	0.067-0.942	0.040	0.352	0.098-1.272	0.111
Parkin (low/high)	0.477	0.241-0.943	0.033	0.431	0.232-0.801	0.008
CEA (low/high)	0.528	0.259-1.079	0.080	0.585	0.305-1.121	0.106
CA19-9 (low/high)	0.943	0.462-1.922	0.871	0.730	0.384-1.389	0.338
P53 (high/low)	1.612	0.799-3.250	0.182	1.854	0.988-3.477	0.054
CDX2 (high/low)	1.237	0.510-3.003	0.638	1.144	0.517-2.529	0.741

OS: Overall survival; PFS: Progression-free survival; HR: Hazard ratio; CI: Confidence interval; PGAM5: Phosphoglycerate mutase family member 5; CEA: Carcinoembryonic antigen.